Therapy via targeted delivery of nanoscale particles
First Claim
1. A targeted thermotherapy system for treating disease material in a patient, the system comprising:
- a) a bioprobe or a bioprobe system comprising a susceptor;
b) an alternating magnetic field (AMF) inducing inductor that produces an AMF to energize the susceptor; and
c) a generator coupled to the inductor to provide power to the AMF inducing inductor.
3 Assignments
0 Petitions
Accused Products
Abstract
Disclosed are compositions, systems and methods for treating a subject'"'"'s body, body part, tissue, body fluid cells, pathogens, or other undesirable matter involving the administration of a targeted thermotherapy that comprises a bioprobe (energy susceptive materials that are attached to a target-specific ligand). Such targeted therapy methods can be combined with at least one other therapy technique. Other therapies include hyperthermia, direct antibody therapy, radiation, chemo- or pharmaceutical therapy, photodynamic therapy, surgical or interventional therapy, bone marrow or stem cell transplantation, and medical imaging, such as MRI, PET, SPECT, and bioimpedance. The disclosed therapies may be useful in the treatment of a variety of indications, including but not limited to, cancer of any type, such as bone marrow, lung, vascular, neuro, colon, ovarian, breast and prostate cancer, epitheleoid sarcomas, AIDS, adverse angiogenesis, restenosis, amyloidosis, tuberculosis, cardiovascular plaque, vascular plaque, obesity, malaria, and illnesses due to viruses, such as HIV.
200 Citations
110 Claims
-
1. A targeted thermotherapy system for treating disease material in a patient, the system comprising:
-
a) a bioprobe or a bioprobe system comprising a susceptor;
b) an alternating magnetic field (AMF) inducing inductor that produces an AMF to energize the susceptor; and
c) a generator coupled to the inductor to provide power to the AMF inducing inductor. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
-
19. A therapeutic method for treating the body, body part, tissue, cell, or body fluid of a subject, comprising:
-
a. administering targeted thermotherapy to a target by supplying a bioprobe to the target and exposing the bioprobe to an alternating magnetic field (AMF), and b. administering at least one other therapy to the target, wherein the at least one other therapy is administered prior to, during, after the targeted thermotherapy administration, or a combination thereof. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 101, 102)
-
-
45. A therapeutic method, comprising:
-
a. administering targeted thermotherapy to a body, body part, or tissue of a subject containing a tumor, by supplying a bioprobe to the body, body part or tissue and exposing the bioprobe to an alternating magnetic field (AMF), and b. destroying or inhibiting the vascularity of the body, body part or tissue in response to exposure to the AMF. - View Dependent Claims (46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)
-
-
72. A therapeutic method for treating the body, body part, tissue, cell, or body fluid of a subject, comprising:
-
a) medically imaging the body, body part, tissue, cell or body fluid; and
b) administering targeted thermotherapy by introducing a bioprobe to the body, body part, tissue, cell or body fluid of the subject and exposing the bioprobe to an alternating magnetic field (AMF), wherein the administering the targeted thermotherapy occurs prior to, during, or after the medical imaging, or a combination thereof. - View Dependent Claims (73, 74, 75, 76, 77)
-
-
78. A magnetic material composition, comprising:
-
a. a particle having magnetic properties and forming a single magnetic domain;
b. a biocompatible coating material for the particle; and
c. a ligand selective to at least one disease material marker associated with disease material, the ligand being i) bound to an uncoated portion of the particle, ii) bound to a coated portion of the particle, iii) bound to the particle and partially covered by the coating or iv) intercalated into the coating. - View Dependent Claims (79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100)
-
-
103. A magnetic material composition, comprising:
-
a. a bioprobe, the bioprobe comprising a particle having magnetic properties associated with a first therapy, and a ligand selective to at least one disease material marker associated with a disease material;
the ligand being associated with the particle; and
b. an agent associated with a second therapy, the agent being associated with the bioprobe. - View Dependent Claims (104, 105, 106, 107, 108, 109, 110)
-
Specification